Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) shares shot up 5.8% during trading on Tuesday . The company traded as high as $1.65 and last traded at $1.65. 175,365 shares were traded during mid-day trading, a decline of 63% from the average session volume of 473,519 shares. The stock had previously closed at $1.56.
Tiziana Life Sciences Stock Down 2.5%
The business has a 50 day moving average price of $1.38 and a 200 day moving average price of $1.09.
Hedge Funds Weigh In On Tiziana Life Sciences
Institutional investors and hedge funds have recently bought and sold shares of the business. Dauntless Investment Group LLC acquired a new position in Tiziana Life Sciences during the first quarter worth $1,879,000. Jane Street Group LLC grew its holdings in Tiziana Life Sciences by 968.2% in the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock valued at $181,000 after buying an additional 151,858 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in Tiziana Life Sciences in the 1st quarter valued at $156,000. Bison Wealth LLC purchased a new stake in Tiziana Life Sciences in the 4th quarter valued at $30,000. Finally, Geode Capital Management LLC grew its holdings in Tiziana Life Sciences by 12.4% in the 4th quarter. Geode Capital Management LLC now owns 245,722 shares of the company's stock valued at $171,000 after buying an additional 27,041 shares in the last quarter.
Tiziana Life Sciences Company Profile
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Read More
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
